Madrigal Pharmaceuticals, Inc. $MDGL Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 31,624 shares of the biopharmaceutical company’s stock, valued at approximately $15,937,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in Madrigal Pharmaceuticals by 27.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock valued at $1,051,727,000 after purchasing an additional 433,804 shares during the period. Jupiter Topco LLC bought a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $1,039,650,000. Paulson & CO. Inc. acquired a new stake in shares of Madrigal Pharmaceuticals during the 2nd quarter worth approximately $719,524,000. BlackRock Inc. acquired a new stake in shares of Madrigal Pharmaceuticals during the 2nd quarter worth approximately $644,753,000. Finally, Wellington Management Group LLP grew its position in shares of Madrigal Pharmaceuticals by 18.8% during the 2nd quarter. Wellington Management Group LLP now owns 825,714 shares of the biopharmaceutical company’s stock worth $443,367,000 after buying an additional 130,756 shares during the period. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Stock Down 8.1%

Shares of MDGL stock opened at $396.32 on Wednesday. The company has a quick ratio of 2.94, a current ratio of 3.20 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average of $494.64 and a 200-day moving average of $498.92. Madrigal Pharmaceuticals, Inc. has a one year low of $387.33 and a one year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The business had revenue of $431.27 million for the quarter, compared to the consensus estimate of $404.17 million. During the same period last year, the company posted ($5.08) EPS. Analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 6,362 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the sale, the chief executive officer directly owned 202,967 shares in the company, valued at approximately $108,707,095.53. This trade represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the sale, the general counsel owned 11,474 shares in the company, valued at approximately $5,908,765.78. This trade represents a 5.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 12,247 shares of company stock valued at $6,581,182. Corporate insiders own 17.60% of the company’s stock.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Madrigal posted Q3 EPS of $1.83, versus analysts’ expectation of a $1.09 loss, and revenue of $431.27 million, above the $404.17 million consensus. The company also said Rezdiffra sales had topped $1 billion, with sales up 50%. Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50%
• Positive Sentiment: Citigroup raised its price target to $760 from $725 and maintained a Buy rating, pointing to substantial potential upside from the recent share price. Citigroup rating information
• Neutral Sentiment: Madrigal expects a late-2027 readout from the MAESTRO-NASH OUTCOMES trial and is planning a study of more than 2,000 patients with compensated cirrhosis and portal hypertension. These programs could broaden the company’s opportunity, but their results are not near-term catalysts. Madrigal trial plans
• Negative Sentiment: Despite the earnings beat, MDGL hit a fresh 52-week low as investors focused on near-term profitability concerns. This suggests the market may be weighing the sustainability of the commercial ramp and future investment needs against Rezdiffra’s growth. MDGL stock and profitability concerns

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MDGL shares. HC Wainwright reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. The Goldman Sachs Group began coverage on shares of Madrigal Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $704.00 target price for the company. Wolfe Research upgraded shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price for the company in a research report on Tuesday, August 4th. Citigroup increased their price target on Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Canaccord Genuity Group raised their price target on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $701.53.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.